Therapeutic value of three-dimensional conformal radiotherapy combined with enzalutamide in patients with hormone-resistant advanced prostate cancer
Objective To study the therapeutic value of three-dimensional conformal radiotherapy combined with enzalu-tamide in patients with hormone-resistant advanced prostate cancer.Methods Sixty patients with advanced prostate cancer who came to our hospital from June 2020 to February 2022 were selected.They were randomly divided into a combi-nation group and a control group,with 30 cases in each group.The control group was given enzalutamide,and the combi-nation group was given three-dimensional conformal radiation therapy on this basis.The clinical efficacy of the two groups after 3 months of treatment was compared,and the tumor markers[prostate-specific antigen(PSA),early prostate canc-er antigen-2(EPCA-2)],symptom scores before and after treatment between the two groups were compared and ana-lyzed.[International Prostate Symptom Score(IPSS)]and quality of life[Life Quality Scale for Patients with Prostate Cancer(FACT-P)];The incidence of toxic and side effects in the two groups during the treatment cycle was compared,and the patients were followed up for 1 year to observe the survival of the patients and do survival curve analysis.Results Compared with the control group after three months of treatment,the patients in the combination group had sig-nificantly better clinical curative effect,and the objective remission rate was significantly higher(P＜0.05).Compared with that before treatment,the levels of various tumor markers,IPSS and FACT-P scores in the two groups were decreased af-ter three months of treatment,and the difference was significant(P＜0.05).The combined group was lower than that of the control group at the same time,and the difference was statistically significant(P＜0.05).There was no significant difference in the toxic and side effects between the two groups within 3 months of treatment(P＞0.05).The survival time of patients in the combined group was longer than that in the control group and the difference was statistically significant(P＜0.05).Conclusion Three-dimensional conformal radiotherapy combined with enzalutamide for the treatment of patients with hormone-resistant advanced prostate cancer can improve the clinical efficacy while controlling the level of serum tumor markers,relieving clinical symptoms and improving the quality of life of patients.The safety is acceptable,and it is beneficial to extend patient progression-free survival and improve disease prognosis.
Three-dimensional conformal radiotherapyEnzalutamideHormone-resistant prostate cancer
NETL
NSTL
万方数据
